From Morningstar: 2024-04-11 06:21:00

Shares in AstraZeneca surged 1.32% after announcing a 7% dividend increase and a crucial vote on CEO Pascal Soriot’s £1.8 million pay package. Shareholders are split over the decision, with top investor Rajiv Jain defending Soriot’s value despite criticism. Analysts view the raise as a strategic move to secure votes.

Amidst the debate, GQG Partners claim Soriot is underpaid given AstraZeneca’s growth under his leadership. The dividend hike to $3.10 per share by 2024 is seen as a tactic to appease shareholders. Despite the controversy, the company’s focus on complex treatments remains strong, keeping investor confidence.

Critics like AJ Bell question whether executive pay in pharmaceuticals has spiraled out of control. While acknowledging Soriot’s contributions, the issue is the scale of his remuneration. AstraZeneca’s stock was trading at £108.74 at the time of writing, highlighting the ongoing investor interest and uncertainty over the CEO’s pay package.



Read more at Morningstar: ‘Barely-Disguised’ Dividend Hike Boosts AstraZeneca…